Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: results from the randomized phase II RE-AKT trial

In this study, we assessed antitumor activity of the AKT inhibitor capivasertib combined with enzalutamide in mCRPC with prior progression on AA and docetaxel.

Source: European Journal of Cancer - May 8, 2024 Category: Cancer & Oncology Authors: Pasquale Rescigno, Nuria Porta, Laura Finneran, Ruth Riisnaes, Ines Figueiredo, Suzanne Carreira, Penny Flohr, Susana Miranda, Claudia Bertan, Ana Ferreira, Mateus Crespo, Daniel Nava Rodrigues, Bora Gurel, Jenny Nobes, Simon Crabb, Zafar Malik, Christy R Tags: Clinical Trial Source Type: research